Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal
tumor necrosis factor α antibody, in combination with methotrexate (MTX) in patients with …

Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …

… , C Guzzo, B Zhou, and L Dooley are employees of Centocor, Inc, Malvern, Pennsylvania,
USA. C Birbara has received research support from Centocor, Inc. We acknowledge C Arnold …

Background Increased expression of nerve growth factor in injured or inflamed tissue is
associated with increased pain. This proof-of-concept study was designed to investigate the …

OBJECTIVE: This study, known as STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis),
evaluated the safety and efficacy of adalimumab (Humira), a fully human monoclonal …

Objective: To evaluate the long-term effectiveness and tolerability of adalimumab in the
treatment of psoriatic arthritis (PsA). Methods: Patients with PsA who completed a 24-week, …

Objective. To evaluate the effect of infliximab on progression of structural damage over 1
year in patients with active psoriatic arthritis (PsA) enrolled in the Induction and Maintenance …

… The effect of apremilast on multiple manifestations of PsA is being assessed in patients
with active PsA in the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) …

Increased nerve growth factor levels are associated with chronic pain conditions, including
chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab…

OBJECTIVE: This study compared the immunogenicity of influenza and pneumococcal
vaccines in adult patients with rheumatoid arthritis (RA) receiving adalimumab or placebo. …